Antiretroviral drugs require 95 percent adherence to work, find researchers at University of Pittsburgh Medical Center

July 05, 2000

Study also finds doctors are often wrong about patients' adherence

PITTSBURGH, July 7 -- A computerized medication monitoring system has shown that HIV patients must be at least 95 percent adherent to antiretroviral therapy for the drugs to work, report investigators from the University of Pittsburgh Medical Center (UPMC). In a startling twist, the study also reveals that physicians often are wrong about their patients' adherence. Results of the study are published in the July 4 issue of the Annals of Internal Medicine.

"For HIV therapy to be effective, patients cannot afford to skip or delay any pills in their daily regimen, and it is vital that doctors know exactly how adherent each patient is," said David L. Paterson, M.D., chief of infectious diseases at UPMC's new hospital in Palermo, Italy, and principal investigator on the study. "However, this study shows that in almost half the cases, physicians are mistaken about their patients' adherence. Those mistakes could have serious consequences."

Physicians in the study miscategorized adherence for 41 percent of their patients. Researchers were especially concerned about physicians' underestimation of a patient's adherence, as this belief may make a physician reluctant to prescribe the complex "drug cocktail." Conversely, overestimation of adherence may lead a physician to change therapies based on a mistaken belief that the drugs are ineffective. In reality, the patient simply may be skipping doses.

The UPMC study involved 81 patients who were taking protease inhibitors. They were patients at HIV clinics at the Veterans Affairs (VA) Medical Center in Pittsburgh and the University of Nebraska Medical Center in Omaha, Neb.

Researchers followed patients' drug adherence with the computerized Medication Events Monitoring System. Microprocessors in medication bottle caps recorded each opening and showed the date, time and duration of opening. Scanning the cap over a communicator module recorded medication dosing. Percentage of adherence was calculated by dividing the number of prescribed doses by the number of doses taken.

Investigators found that the degree of adherence was directly related to the outcome of drug therapy. Patients with 95 percent or greater adherence had a greater chance of success, as measured by disappearance of detectable HIV in their bloodstream, greater increases in CD4 lymphocyte count (a major marker of HIV infection) and lower hospitalization rates than did patients with levels of adherence lower than 95 percent.

"The results of this study have significant implications for the thousands of patients who are currently on HIV drug therapy," said Nina Singh, M.D., director of the HIV clinic at the VA Medical Center in Pittsburgh, associate professor of medicine at the University of Pittsburgh and co-principal investigator on the study. "Doctors realize that the drug regimens are difficult, but without a high degree of adherence, the medications will be ineffective."

Of concern to investigators is the fact that only 28 percent of patients studied were able to reach the required 95 percent level of adherence. Those patients with low adherence were more likely to have problems with alcoholism and depression than were those with at least a 95 percent adherence level.

"Clearly, we must increase our efforts to diagnose and treat active depression in patients infected with HIV as a potential strategy to improve adherence," said Dr. Paterson. "Numerous studies on medication adherence have associated the presence of psychiatric illness with decreased adherence to therapy, and in this case it can be a matter of life and death."
Alternate contact: Lauren Ward
PHONE: 412-624-2607
FAX: 412-624-3184

UPMC Health System is the leading integrated delivery system for health care in western Pennsylvania. For information on UPMC Health System, access

University of Pittsburgh Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to